SERPINB2 and cancer: Similarly, aberrant activation of SERPINB2 has been reported to be significantly associated with tumor progression (metastasis) and poor prognosis in various cancer types, such as endometrial [74], colorectal [75], ovarian [76], and bladder [77] cancers.